Financing ·
On August 3, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital…
OTLCOncotelic Therapeutics, Inc.
On August 3, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note with an aggregate gross principal amount of $178,410. The note carries a 12% original issue discount and a 12% annual interest rate, maturing one year from issuance or upon acceleration due to default. Conversion is permitted at the holder's option into common stock at $0.06 per share or 85% of the lowest traded price over the preceding ten trading days. The company also issued 500,000 commitment shares to the investor. Oncotelic Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.